Xiaojun Dai

Dr. Xiaojun Dai


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
HWHaibo Wang
Haibo Wang
YLYuanyuan Luo
Yuanyuan Luo
ZCZewen Chu
Zewen Chu
TNTengyang Ni
Tengyang Ni
SOShiya Ou
Shiya Ou
YLYanqing Liu
Yanqing Liu
Background: Poria cocos (P. cocos) is an important medicinal fungus in traditional Chinese medicine. Poria acid (PA), a triterpenoid compound, is an effective component of traditional Chinese medicine P. cocos. This experiment investigated the anti-gastric cancer biological activity of PA in vitro. Methods: The effect of PA on the viability of gastric cancer cells was detected by the thiazolyl blue (MTT) assay. Cell adhesion assays were used to detect changes in the adhesion of cells treated after PA (0, 20, 40, and 80 µmol/L). The ability of cell invasion and migration were detected by Transwell assays and wound healing assays. A high-content imaging system was used to dynamically record the motility of the gastric cancer cells after PA (0, 20, 40, and 80 µmol/L) treatment. Western blotting was used to detect the expression of epithelial–mesenchymal transformation (EMT), invasion and migration related proteins. Results: The MTT assay showed that the proliferation of gastric cancer cells was significantly inhibited after PA treatment. Cell adhesion experiments showed that the adhesion of gastric cancer cells was significantly decreased after PA treatment. Compared with the control group, the wound healing area of the gastric cancer cells treated with different concentrations of PA decreased. The Transwell assay showed that the number of gastric cancer cells passing through the cell membrane were significantly reduced after PA treatment. In addition, after PA treatment, the cells’ movement distance and average movement speed were significantly lower than those of the control group. Finally, PA can significantly alter the expression of EMT-related proteins E-cadherin, N-cadherin, and Vimentin and decreased the expressions of metastasis-related proteins matrix metalloproteinase (MMP) 2, MMP-9 and tissue inhibition of matrix metalloproteinase (TIMP)1 in the gastric cancer cells. Conclusions: Triterpenoids from P. cocos have significant biological activity against gastric cancer, and the mechanism may be involved in the process of epithelial–mesenchymal transformation.

20 October 2023 in Heliyon
Verified
Journal Article
Open access
XDXiaojun Dai
Xiaojun Dai
YYYanwei Yu
Yanwei Yu
CZChen Zou
Chen Zou
BPBo Pan
Bo Pan
HWHaibo Wang
Haibo Wang
YLYanqing Liu
Yanqing Liu
Banxia Xiexin decoction (BXD) is a classic traditional Chinese medicine (TCM) formula clinically used to treat chronic gastritis, gastric ulcers, gastric cancer, and many other gastrointestinal diseases. Long noncoding RNAs (lncRNAs) have been shown to play an important role in maintaining the malignant phenotype of tumors. However, no relevant studies have shown whether Banxia Xiexin decoction regulates and controls lncRNA TUC338, and the effect of TUC338 on the regulation of gastric cancer invasion and metastasis remains unclear. To investigate the ability of the traditional Chinese medicine (TCM) Banxia Xiexin decoction (BXD) to inhibit the migration and invasion of human gastric cancer AGS cells by regulating the long noncoding RNA (lncRNA) TUC338. UHPLC‒MS/MS was used to analyze the chemical components of BXD. MTT was performed to determine the effects of BXD on the proliferation of AGS cells. qRT‒PCR was used to determine the expression of lncRNA TUC338 in gastric cancer tissues, paracarcinoma tissues, AGS human gastric cancer cells and GES-1 normal gastric mucosa cells and to evaluate the effects of BXD on the expression of lncRNA TUC338 in AGS cells. Lentiviral transfection was used to establish human gastric cancer AGS cells with knocked down lncRNA TUC338 expression. The effects of lncRNA TUC338 knockdown on the migration and invasion of AGS cells were observed by a scratch assay and Transwell migration assay, respectively. Western blotting was performed to analyze the effects of lncRNA TUC338 knockdown on epithelial-to-mesenchymal transition (EMT) in AGS cells. We performed quality control on three batches of BXD. We used UHPLC‒MS/MS to control the quality of three random batches of BXD used throughout the study. Ninety-five chemical components were identified from the water extract of BXD, some of which have anticancer effects. The expression of TUC.338 in gastric cancer tissues was higher than that in para-carcinoma tissues. BXD inhibited the invasion and migration of gastric cancer cells by inhibiting the expression of lncRNA TUC338, which reduced EMT. After knockdown of lncRNA TUC338, the migration and invasion of AGS cells were reduced; the expression of the EMT-related protein E-cadherin was increased, and the expression of N-cadherin and vimentin was reduced. The present results suggest that BXD has potential as an effective treatment for gastric cancer through the inhibition of lncRNA TUC338 expression.

18 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
HWHaibo Wang
Haibo Wang
YLYuanyuan Luo
Yuanyuan Luo
YHYaqi Hu
Yaqi Hu
XFXinyi Feng
Xinyi Feng
JFJun Feng
Jun Feng
YLYanqing Liu
Yanqing Liu
Cancer is one of the greatest threats to human health. Gastric cancer (GC) is the fifth most common malignant tumor in the world. Invasion and metastasis are the major difficulties in the treatment of GC. Herbal medicines and their extracts have a lengthy history of being used to treat tumors in China. The anti-tumoral effects of the natural products derived from herbs have received a great deal of attention. Our previous studies have shown that the traditional Chinese herb Celastrus orbiculatus Thunb extract (COE) can inhibit the invasion and metastasis of GC cells, but the specific anti-cancer components of COE are still unclear. Dozens of natural products from COE have been isolated and identified by HPLC spectroscopy in our previous experiments. Triptonoterpene is one of the active ingredients in COE. In this study, we focused on revealing whether Triptonoterpene has an excellent anti-GC effect and can be used as an effective component of Celastrus orbiculatus Thunb in the treatment of tumors. We first observed that Triptonoterpene reduces GC cell proliferation through CCK-8 assays and colony formation experiments. The cell adhesion assays have shown that Triptonoterpene inhibits adhesion between cells and the cell matrix during tumor invasion. In addition, the cell migration assay has shown that Triptonoterpene inhibits the invasion and migration of GC cells. The high-connotation cell dynamic tracking experiment has also shown the same results. The effects of Triptonoterpene on epidermal mesenchymal transition (EMT)-related and matrix metalloproteinases (MMPs)-related proteins in gastric cancer cells were detected by Western blots. We found that Triptonoterpene could significantly inhibit the changes in EMT-related and invasion and metastasis-related proteins. Altogether, these results suggest that Triptonoterpene is capable of inhibiting the migration and invasion of GC cells. Triptonoterpene, as a natural product from Celastrus orbiculatus Thunb, has significant anti-gastric cancer effects, and is likely to be one of the major equivalent components of Celastrus orbiculatus Thunb.

28 October 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MLMin Li
Min Li
JZJingyu Zhang
Jingyu Zhang
JZJundi Zheng
Jundi Zheng
CWChangjin Wu
Changjin Wu
ZSZuting Shao
Zuting Shao
XDXiaojun Dai
Xiaojun Dai
Background: Electronic patient-reported outcomes (ePROs)–based cancer symptom management presents an opportunity to improve patient outcomes by optimizing symptom detection and prompting clinician interventions in tertiary hospitals. However, real-world evidence is limited, especially in primary health care (PHC) settings, which are accompanied by more complex and unknown influencing factors. Objective: We conducted a qualitative study to identify facilitators and barriers associated with the implementation of ePRO-based symptom management in China’s PHC settings under the implementation science (IS) framework. We further developed strategies and recommendations for real-world practices and health policies. Methods: This qualitative study was conducted from October to December 2023 in 9 purposively selected PHC institutions (5 urban and 4 rural) across 5 administrative districts of Yangzhou, Jiangsu Province, China. Community-dwelling patients with cancer, PHC providers, and medical supervisors participated in semistructured interviews and focus group discussions. We used 2 subframeworks under the IS framework—the Consolidated Framework for Implementation Research and Expert Recommendations for Implementing Change—to conduct data analysis and generate strategies. Results: A total of 72 individuals were invited to participate in this study, including 35 community-dwelling patients with cancer (median 66, IQR 60-71.5 years; n=21, 60% men) and 23 PHC personnel (median 45, IQR 27-51 years; n=12, 52.17% men) who participated in semistructured interviews, and 14 medical supervisors (median 47.5, IQR 36.5-54 years; n=10, 71.43% men) who participated in focus group discussions. This study identified 29 barriers and 21 facilitators, and then developed 13 strategies. Crucial challenges include PHC providers’ low self-efficacy and unclear role identification, coupled with community-dwelling patients’ mistrust of primary care, cancer stigma, and fatalistic beliefs, which further reduce motivation; poor integration of ePRO with existing workflows and the absence of performance incentive mechanisms; a lack of nationwide standardized implementation guidelines and quality evaluation criteria; and outdated medical equipment and a limited range of medications. Common challenges included weak collaborative relationships and insufficient funding. Conclusions: Grounded in the IS framework, our study identifies 3 critical priorities for implementing ePRO-based cancer symptom management in PHC settings, including addressing individual-level motivational deficiencies among community-dwelling patients with cancer and PHC providers by resolving misconceptions, bridging knowledge gaps, and establishing supportive incentives; developing supportive medical partnerships and advancing tiered management systems to empower PHC settings; and creating standardized operational guidelines with clear workflows and implementing real-world data-driven regulatory feedback mechanisms to ensure quality control.

4 June 2025 in JMIR Preprints
Verified
Preprint
Open access
MLMin Li
Min Li
JZJingyu Zhang
Jingyu Zhang
JZJundi Zheng
Jundi Zheng
CWChangjin Wu
Changjin Wu
ZSZuting Shao
Zuting Shao
XDXiaojun Dai
Xiaojun Dai
BACKGROUND Electronic patient-reported outcomes (ePROs)–based cancer symptom management presents an opportunity to improve patient outcomes by optimizing symptom detection and prompting clinician interventions in tertiary hospitals. However, real-world evidence is limited, especially in primary health care (PHC) settings, which are accompanied by more complex and unknown influencing factors. OBJECTIVE We conducted a qualitative study to identify facilitators and barriers associated with the implementation of ePRO-based symptom management in China’s PHC settings under the implementation science (IS) framework. We further developed strategies and recommendations for real-world practices and health policies. METHODS This qualitative study was conducted from October to December 2023 in 9 purposively selected PHC institutions (5 urban and 4 rural) across 5 administrative districts of Yangzhou, Jiangsu Province, China. Community-dwelling patients with cancer, PHC providers, and medical supervisors participated in semistructured interviews and focus group discussions. We used 2 subframeworks under the IS framework—the Consolidated Framework for Implementation Research and Expert Recommendations for Implementing Change—to conduct data analysis and generate strategies. RESULTS A total of 72 individuals were invited to participate in this study, including 35 community-dwelling patients with cancer (median 66, IQR 60-71.5 years; n=21, 60% men) and 23 PHC personnel (median 45, IQR 27-51 years; n=12, 52.17% men) who participated in semistructured interviews, and 14 medical supervisors (median 47.5, IQR 36.5-54 years; n=10, 71.43% men) who participated in focus group discussions. This study identified 29 barriers and 21 facilitators, and then developed 13 strategies. Crucial challenges include PHC providers’ low self-efficacy and unclear role identification, coupled with community-dwelling patients’ mistrust of primary care, cancer stigma, and fatalistic beliefs, which further reduce motivation; poor integration of ePRO with existing workflows and the absence of performance incentive mechanisms; a lack of nationwide standardized implementation guidelines and quality evaluation criteria; and outdated medical equipment and a limited range of medications. Common challenges included weak collaborative relationships and insufficient funding. CONCLUSIONS Grounded in the IS framework, our study identifies 3 critical priorities for implementing ePRO-based cancer symptom management in PHC settings, including addressing individual-level motivational deficiencies among community-dwelling patients with cancer and PHC providers by resolving misconceptions, bridging knowledge gaps, and establishing supportive incentives; developing supportive medical partnerships and advancing tiered management systems to empower PHC settings; and creating standardized operational guidelines with clear workflows and implementing real-world data-driven regulatory feedback mechanisms to ensure quality control.

1 February 2026 in Digital Health
Verified
Journal Article
Open access
CWChangjin Wu
Changjin Wu
JZJingyu Zhang
Jingyu Zhang
XWXuqing Wang
Xuqing Wang
JZJundi Zheng
Jundi Zheng
MLMin Li
Min Li
XDXiaojun Dai
Xiaojun Dai
Background: Electronic patient-reported outcomes (ePRO) are valuable for cancer symptom monitoring, but implementation in resource-limited primary health care remains challenging. Identifying stakeholder preferences regarding implementation strategies is crucial for facilitating the adoption and effectiveness of ePRO-based cancer symptom management. Objective: This study aimed to prioritize optimal implementation strategies for ePRO-based cancer symptom management in Chinese primary health care, considering stakeholder preferences. Methods: A best–worst scaling was conducted among stakeholders. Thirteen implementation strategies, derived through qualitative research and implementation science frameworks, were assessed. Preferences were analyzed using count analysis, conditional logit model (CLM), mixed logit model (MLM), and latent class analysis (LCA). Results: A total of 169 respondents were included in the final analysis. Count analysis identified the top three preferred strategies as developing tiered cancer management through ePRO (standardized BW = 0.32), providing evidence-based practice (EBP) incentives (standardized BW = 0.20), and engaging stakeholders (standardized BW = 0.14). Least preferred were disseminating paper/web-based ePRO-related materials (standardized BW = –0.28) and developing ePRO toolkits (standardized BW = –0.25). CLM and MLM results aligned with count analysis, with tiered cancer management through ePRO having the highest odds ratios (OR = 3.20 for CLM, 4.37 for MLM), followed by EBP incentives (OR = 2.55 for CLM, 3.12 for MLM) and stakeholder engagement (OR = 2.25 for CLM, 3.13 for MLM). LCA identified five stakeholder subgroups with distinct preference patterns based on professional roles and settings, including: favorability towards tiered cancer management through ePRO (class 1), preferences for disseminating paper/web-based ePRO-related materials (class 2), financial incentives among younger practitioners and healthcare administrators (classes 3 and 4), and prioritization of stakeholder engagement (class 5). However, tiered cancer management through ePRO were relatively highly preferred across all groups. Conclusions: Tailoring ePRO implementation to stakeholder preferences is crucial. Tiered cancer management was universally preferred, while other strategies varied by professional role. Future research should focus on longitudinal evaluations and economic assessments.